Key result
Transradial percutaneous coronary intervention was associated with a lower risk of 30-day major bleeding and mortality compared to transfemoral access in patients with high bleeding risk, but not in those without.
Why the study?
It was unknown whether the clinical benefits of transradial versus transfemoral PCI differ between high bleeding risk (HBR) and non-HBR patients.
Does transradial PCI reduce 30-day major bleeding and mortality compared to transfemoral PCI in patients with or without high bleeding risk?
Cohort (n=6,828)
Yes
Does transradial PCI reduce 30-day major bleeding and mortality compared to transfemoral PCI in patients with or without high bleeding risk?
Transradial access for PCI is associated with a significant reduction in 30-day major bleeding and mortality compared to transfemoral access specifically in patients with high bleeding risk, supporting its preferential use in this vulnerable population.
Answers are grounded in this paper and cite their sources.
May favor transradial PCI in HBR patients; hypothesis-generating and requires randomized confirmation.
BACKGROUND: The transradial approach is reportedly associated with reduced bleeding complications and mortality after percutaneous coronary intervention (PCI). It is unknown whether the clinical benefits of transradial vs. transfemoral PCI differ between high bleeding risk (HBR) and non-HBR patients. METHODS AND RESULTS: After excluding patients with acute myocardial infarction, dialysis, and a transbrachial approach from the 13,087 patients undergoing first PCI in the CREDO-Kyoto Registry Cohort-2, 6,828 patients were eligible for this study. Patients were divided into 2 groups according to bleeding risk based on Academic Research Consortium HBR criteria, and then divided into a further 2 groups according to access site, radial or femoral: HBR-radial, n=1,054 (38.3%); HBR-femoral, n=1,699 (61.7%); non-HBR-radial, n=1,682 (41.3%); and non-HBR-femoral, n=2,393 (58.7%). In the HBR group, the 30-day incidence and adjusted risk for major bleeding (1.9% vs. 4.7% [P<0.001]; adjusted hazard ratio [aHR] 0.44, 95% confidence interval [CI] 0.26-0.71 [P<0.001]) and all-cause death (0.3% vs. 0.9% [P=0.04]; aHR 0.30, 95% CI 0.07-0.93 [P=0.04]) were significantly lower in the radial than femoral group. There were no significant differences in the 30-day incidence and adjusted risk for major bleeding (0.5% vs. 1.0% [P=0.09]; aHR 0.68, 95% CI 0.30-1.45 [P=0.33]) or all-cause death (0.1% vs. 0.1% [P=0.96]; aHR 1.51, 95% CI 0.19-9.54 [P=0.67]) between the radial and femoral approaches in the non-HBR group. CONCLUSIONS: Compared with transfemoral PCI, transradial PCI was associated with lower risk for 30-day major bleeding and mortality in HBR but not non-HBR patients.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2020) conducted a cohort in Coronary artery disease requiring percutaneous coronary intervention (n=6,828). Transradial percutaneous coronary intervention vs. Transfemoral percutaneous coronary intervention was evaluated on 30-day major bleeding (GUSTO moderate/severe) in high bleeding risk (HBR) patients (aHR 0.44, 95% CI 0.26-0.71, p=<0.001). Transradial percutaneous coronary intervention was associated with a lower risk of 30-day major bleeding and mortality compared to transfemoral access in patients with high bleeding risk, but not in those without.
Synapse has enriched 10 related papers. Consider them for comparative context: